Interview with Afreen Allam, Founder & CEO at SiNON Nano and Laura Gunter, President at NC Life Sciences By Caitlin Dolegowski, Marketing Manager, LSN
 Afreen Allam |
 Laura Gunter |
 Caitlin Dolegowski |
The next opportunity to participate in the Innovator’s Pitch Challenge will be at RESI Europe and the deadline to apply has been extended until May 15th.
The IPC increases companies’ visibility by giving them the opportunity to pitch to a select investor panel and live audience, present a poster in the RESI Exhibition Hall, and get featured in the RESI Program Guide and Newsletter. Finalists in the IPC make more investor connections at RESI thanks to this additional visibility. Applications are accepted on a rolling basis, and you can apply here.
Caitlin Dolegowski (CD): Afreen, please introduce us to SiNON Nano Sciences and the company’s technology.
Afreen Allam (AA): SiNON has pioneered a revolutionary approach with our patented tunable carbon nanoparticle, serving as a ‘Trojan horse’ drug delivery platform. This innovative technology facilitates the passage of drugs across the blood-brain barrier, unlocking new possibilities in treating a myriad of neurological diseases. Our platform empowers pharmaceutical companies to encapsulate their therapeutics, enabling precise drug delivery to targeted sites within the brain. As the nanoparticle traverses the barrier, the drug payload is released, offering a potent solution for enhancing treatment efficacy while minimizing side effects and toxicity. This breakthrough holds the potential to significantly enhance the quality of life for millions of patients worldwide.
CD: Laura, please introduce us to North Carolina Life Sciences. There is exciting technology coming from your state. Four companies were presenting at RESI South from North Carolina. What stands out for you about the technology in North Carolina and SiNON Nano Sciences in particular?
Laura Gunter (LG): North Carolina has tremendous universities and early-stage companies doing exciting research in so many areas. The companies that presented at RESI from NC are working in diagnostics, drug delivery, AI, infusion devices, and neurological conditions, including sleep monitoring and Alzheimer’s. SiNON Nano Sciences is particularly exciting as a platform technology that has the potential to change how we can treat CNS diseases. The ability to take a drug across the blood-brain barrier is a game changer.
CD: What were your experiences at the conference? What worked well for you both at RESI South?
AA: Attending the RESI (Redefining Early Stage Investments) conference was an enriching experience for me. It provided a unique platform for networking with investors, fellow entrepreneurs, and industry experts. The event offered valuable insights into the latest trends, innovations, and opportunities in the life sciences and healthcare sectors.
One of the highlights was participating in the Innovator’s Pitch Challenge, where we had the opportunity to showcase our company’s vision and technology to a panel of esteemed judges and investors. Winning the first-place prize in the pitch competition was a significant achievement for us and served as validation of the potential impact of our work.
Moreover, the conference sessions and panel discussions were highly informative, covering a wide range of topics such as fundraising strategies, regulatory considerations, and market trends. Engaging with other attendees and hearing their perspectives provided valuable learning opportunities and helped us refine our business strategy.
Overall, the RESI conference provided a conducive environment for fostering collaborations, exploring partnerships, and gaining visibility for our venture. It was an invaluable experience that has contributed to the growth and advancement of our company in the life sciences ecosystem.
LG: I thought it was a great first opportunity to bring investors to the Southeast and see the breadth and depth of technologies in the SE. While several of the NC companies were from the RTP area, we also had a company from Wilmington, NC, so it was nice to highlight the geographic diversity as well. The feedback from our participating companies was good and it sounded like several made some relevant connections.
The panels were also informative and gave entrepreneurs a chance to hear from investors, in addition to pitching to investors. The quality of the presenting companies was impressive as well.
It was, of course, very exciting to have SiNON win the pitch competition. When I first talked to Afreen about the company, I could tell it was special, so was glad to be able to bring them to RESI and have others learn about the company as well.
CD: What stage of fundraising is SiNON Nano Sciences in and what are your goals in 2024?
AA: SiNON Nano Sciences is currently in the seed stage of fundraising. Our primary goal for 2024 is to successfully secure funding for our seed round, which will enable us to advance our research and development efforts. Specifically, we aim to conduct the two main studies necessary to determine whether we are positioned as a platform or an asset company. Additionally, we plan to continue building strategic partnerships, expanding our network within the life sciences and healthcare sectors, and further refining our technology to address the unmet needs in treating neurological diseases. Our overarching goal is to advance our innovative drug delivery platform to improve the lives of patients suffering from debilitating neurological conditions.
The terms for our upcoming seed raise entail a $3 million SAFE (Simple Agreement for Future Equity) agreement with a 20% discount and a post-money valuation cap of approximately $15 million.
CD: Congratulations on your first-place finish at RESI JPM’s Innovator’s Pitch Challenge (IPC)! There were 43 companies in the IPC. What do you think was the key to your success and standing out at RESI JPM?
AA: Thank you! Winning the RESI JPM’s Innovator’s Pitch Challenge was an incredible achievement for us. I believe the key to our success and standing out at RESI JPM was our ability to clearly articulate the unique value proposition of SiNON Nano Sciences. Our focus on developing a patented carbon nanoparticle drug delivery platform, specifically designed to overcome the challenges of crossing the blood-brain barrier for treating neurological diseases, resonated strongly with the audience and judges. Additionally, our ability to highlight compelling data supporting the efficacy and potential impact of our technology played a crucial role in distinguishing us from other companies. Finally, our team’s passion, dedication, and clear vision for the future of SiNON Nano Sciences also contributed to our success at RESI JPM’s IPC.
CD: What advice would you like to give to fellow entrepreneurs about RESI conferences?
AA: For fellow entrepreneurs attending RESI conferences, I would offer the following advice:
- Prepare a compelling pitch: Craft a concise and engaging pitch that clearly communicates your company’s value proposition, market opportunity, and traction. Highlight what sets your company apart and why investors should be interested.
- Network strategically: Take advantage of the networking opportunities at RESI conferences to connect with investors, industry experts, and potential partners. Be proactive in initiating conversations and building relationships that could benefit your company in the future.
- Showcase data and results: Investors are often interested in seeing tangible evidence of progress and potential success. Make sure to showcase any compelling data, results, or achievements that demonstrate the viability and scalability of your business.
- Be open to feedback: Embrace feedback and use it as an opportunity to learn and improve. Investors may provide valuable insights and perspectives that can help refine your business strategy and pitch.
- Follow up promptly: After the conference, follow up promptly with investors and contacts you met to express gratitude, provide additional information, and continue the conversation. Building and maintaining relationships is key to long-term success in fundraising and business development.
LG: I am not sure I can improve upon Afreen’s assessment and advice. Preparation is key and having a succinct message that clearly articulates the technology, its stage, its value proposition, etc. will win the day. Investors are trying to cut through a lot of noise and pitch, like SiNON’s that told the story in an easy to follow but highly competent and technical manner can really make the difference.
Follow up to networking and developing relationships is also key. The investor who is not necessarily interested today may be interested in the future as further development takes place or that investor may know others who would be good fits for the technology.
Lastly, while the pitch competition is a terrific opportunity, I would suggest that companies attend to network and learn, even if they choose not to do the pitch competition. That way, they can get a feel for partnering and using the system to be successful.
